Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting


Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022


After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

AstraZeneca to fork out $815 million for rights to anemia drug candidate


In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Japan launches for Lotriga and Argamate


Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

AVEO and Astellas file NDA for tivozanib in kidney cancer


USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

Astellas debuts Kiklin capsules, for hyperphosphatemia, in Japan


Japanese drug major Astellas Pharma (TYO: 4503) yesterday launched Kiklin capsules 250mg (bixalomar)…

Asia-PacificAstellas PharmaKiklinMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Astellas and Sanwa to co-promote kidney disease drugs in Japan


Japanese drug major Astellas Pharma (TYO: 4503) yesterday revealed that it has linked up with fellow…

ArgamateAsia-PacificAstellas PharmabixalomerMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial


US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas…

Astellas PharmaAVEO PharmaceuticalsBayerBiotechnologyNephrology and HepatologyNexavarOncologyPharmaceuticalRegulationResearchtivozanib



Back to top